A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Phase of Trial: Phase I/II
Latest Information Update: 28 Jan 2016
Price : $35 *
At a glance
- Drugs Birinapant (Primary) ; Conatumumab
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors TetraLogic Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 13 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.